Repligen acquires Novozymes business for $23 million

Friday, October 28, 2011

Repligen has acquired the business of Novozymes Biopharma Sweden in a cash $22.7 million and future potential milestone payments of $5.6 million. This acquisition will elevate Repligen to a world-leading supplier of products for manufacturing biologic drugs with the potential to yield sustainable growth and profitability in fiscal year 2013, beginning April 1, 2012. The combined company is expected to generate total revenues of approximately $50 million in fiscal year 2013.

[Read More]

Repligen reports phase IIb failure

Wednesday, March 9, 2011

Waltham, Mass.-based Repligen said its phase IIb study of RG2417, an oral formulation of uridine, failed to reflect a statistically significant distance between the bipolar depression drug and a placebo.

[Read More]